Fifth Third Bancorp Common Stock vs Medpace Holdings Inc — how do they compare? Fifth Third Bancorp Common Stock trades at $50.42 (market cap $45.98B), while Medpace Holdings Inc trades at $614.07 (market cap $16.82B). The key difference: Fifth Third Bancorp Common Stock is far larger — about 2.7× Medpace Holdings Inc's market cap, and Fifth Third Bancorp Common Stock pays a 3.31% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fifth Third Bancorp Common Stock for 1 Days and Medpace Holdings Inc for 14 Days on average.
| FITB | MEDP | |
|---|---|---|
Market Cap | $45.98B | $16.82B |
Volume | 10,522,320 | 223,093 |
Sector | Financials | Health |
52-Week High | $59.37 | $630.19 |
52-Week Low | $40.36 | $393.42 |
Typical Hold Time | 1 Days | 14 Days |
Enterprise Value | $63.85B | $16.44B |
Dividend Yield | 3.31% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Fifth Third Bancorp provides retail and commercial banking, lending, payments, and wealth management services in the United States.
Read more on FITB →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →